论文部分内容阅读
我们对44例病毒性肝炎肝组织进行了蛋白依赖酶(CDK)活性抑制因子 P21、P15蛋白免疫组化研究。取44例我院肝穿刺活检肝组织、经病理诊断,急性肝炎12例,慢性肝炎18例,肝炎后肝硬变6例,原发性肝癌8例。44例患者中男性38例,女性6例,年龄21～65岁。肝组织经10%中性福尔马林固定,常规石蜡包埋,切成4um 连续切片,分别作 HE及免疫组化染色。免疫组化采用 LSAB 法(Dako 公司产品),抗人 P21、P15抗体(美国 ZYMED 公司产品),工作浓度为1:300。结果:P21、P15蛋白在肝组织表达部位基本一致,主要表达在汇管区间质、碎屑样坏死区周围和小叶内的肝细胞核和/
In 44 cases of viral hepatitis, we carried out immunohistochemical studies on P21 and P15, protein-dependent enzyme (CDK) inhibitors. Totally 44 cases of liver biopsy in our hospital were diagnosed by pathology. There were 12 cases of acute hepatitis, 18 cases of chronic hepatitis, 6 cases of posthepatitic cirrhosis and 8 cases of primary liver cancer. Among the 44 patients, 38 were male and 6 were female, ranging in age from 21 to 65 years. Liver tissue was fixed in 10% neutral formalin, embedded in paraffin and cut into 4um serial sections for HE and immunohistochemical staining respectively. Immunohistochemistry using LSAB method (Dako company), anti-human P21, P15 antibody (the United States ZYMED company), the working concentration of 1: 300. Results: The expression of P21 and P15 protein in liver tissues were basically the same, mainly expressed in the interstitial area of the portal area, around the debris-like necrosis area and within the hepatocytes and /